Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will present its ...

About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has determined the strategic priorities for the ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Nephritic syndrome with low complement levels and pancytopenia point to childhood-onset SLE as a unifying diagnosis. This diagnosis also would explain the polyarthritis and intracranial hypertension.

Roughly one-fifth of American adults consume diet sodas on a given day. The market is huge — more than $5 billion globally — ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on KYTX stock, giving a Buy rating on January 13.Stay Ahead of the ...

Michael Ulz, an analyst from Morgan Stanley, maintained the Buy rating on Kyverna Therapeutics, Inc. (KYTX – Research Report). The associated ...

HC Wainwright reiterated their buy rating on shares of Cabaletta Bio (NASDAQ:CABA – Free Report) in a report issued on Friday ...

Shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) have received an average rating of “Buy” from the nine research ...

Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the ...

While many patients showed improvement in Fanconi syndrome — a condition where ... 50% exhibited tubulointerstitial nephritis (inflammation), while 32% showed evidence of tubular necrosis.

The final diagnosis was secondary CNSV due to systemic lupus erythematosus with catastrophic antiphospholipid syndrome and nephritic syndrome with renal biopsy‐proven thrombotic microangiopathy. Her ...